Overview

Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects

Status:
Completed
Trial end date:
2007-12-06
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Dutasteride